Compare Moderna, Inc. (MRNA) vs Novagold Resources Inc. (NG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Novagold Resources Inc. — how do they compare? Moderna, Inc. trades at $241.3 (market cap $90.35B), while Novagold Resources Inc. trades at $6.29 (market cap $2.73B). The key difference: Moderna, Inc. is far larger — about 33.1× Novagold Resources Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Novagold Resources Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Novagold Resources Inc. for 0 Days on average.
| MRNA | NG | |
|---|---|---|
Market Cap | $90.35B | $2.73B |
Volume | 16,579,584 | 6,599,188 |
Sector | Health | Basic Materials |
52-Week High | $226.30 | $14.20 |
52-Week Low | $22.36 | $5.18 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $86.50B | $2.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative net income margins (-142.58%) and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock has rallied over 500% in 2026, creating valuation concerns with a P/S ratio of 40.29.
While Nasdaq inclusion and cancer vaccine pipeline progress offer upside potential, Moderna's high valuation and persistent losses present significant risk. Analyst consensus is mixed with a $115.70 price target below current levels, indicating cautious sentiment despite recent momentum. Investors face tension between growth prospects and financial sustainability.
NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.
The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Novagold Resources Inc.
NovaGold Resources Inc. is a mineral exploration and development company that holds a majority interest in the Donlin Gold project, an undeveloped gold deposit in Alaska.
Read more on NG →
